Search alternatives:
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
greater decrease » greater increase (Expand Search), greater increases (Expand Search), rate decreased (Expand Search)
linear decrease » linear increase (Expand Search)
mean decrease » a decrease (Expand Search)
Showing 12,881 - 12,900 results of 55,503 for search '(( a ((mean decrease) OR (linear decrease)) ) OR ( a ((largest decrease) OR (greater decrease)) ))', query time: 0.65s Refine Results
  1. 12881
    Study outcomes.

    Study outcomes. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  2. 12882
    Effect of let-7a on expression of E2F2 and CCND2.

    Effect of let-7a on expression of E2F2 and CCND2. by Qingchuan Dong (250327)

    Published 2010
    “…After transfected with let-7a, the expression levels of E2F2, CCND2, and k-ras decreased dramatically in PC3-let-7a-GFP cells compared with that in PC3-GFP cells. β-actin was used the loading control.…”
    Save to List
    Saved in:
  3. 12883
    <i>NAB3</i> reduces the level of <i>IMD2</i> CUT terminator readthrough product from a reporter and native <i>IMD2</i> CUT and readthrough RNA, but <i>NAB3</i> does not significantly affect the termination of native <i>IMD2</i> CUT in <i>air1/2</i> cells.

    <i>NAB3</i> reduces the level of <i>IMD2</i> CUT terminator readthrough product from a reporter and native <i>IMD2</i> CUT and readthrough RNA, but <i>NAB3</i> does not significant... by Milo B. Fasken (659389)

    Published 2015
    “…<i>nab3-R331A</i>, <i>nab3-F333A</i>, and <i>nab3-S399A</i> RRM mutants do not decrease level of GFP from pREF-GFP reporter in <i>air1/2</i> cells. …”
    Save to List
    Saved in:
  4. 12884
    Rhinorrhea-free days up to day 10.

    Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  5. 12885
    Vomit-free days up to day 10.

    Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  6. 12886
    Symptoms free-days up to day 10.

    Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  7. 12887
    Respiratory symptoms-free days up to day 10.

    Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  8. 12888
    Other symptoms-free days up to day 10.

    Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  9. 12889
    Diarrhea-free days up to day 10.

    Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  10. 12890
    Gastrointestinal symptoms-free days up to day 10.

    Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  11. 12891
    Nausea-free days up to day 10.

    Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  12. 12892
    Flow of patients in Halos trial.

    Flow of patients in Halos trial. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  13. 12893
    Cough-free days up to day 10.

    Cough-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  14. 12894
    Dyspnea-free days up to day 10.

    Dyspnea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  15. 12895
    Several components contribute to detection of the mixture.

    Several components contribute to detection of the mixture. by Majid Ghaninia (37312)

    Published 2022
    “…(A) In <i>Apis mellifera</i> omission of phenylacetaldehyde, nonanal, decanal, acetophenone, and p-anisaldehyde from the blend significantly decreased the responses elicited by the OSNs. …”
    Save to List
    Saved in:
  16. 12896
    Spatial distribution of 12 class B notifiable infectious diseases in China: A retrospective study

    Spatial distribution of 12 class B notifiable infectious diseases in China: A retrospective study by Bin Zhu (182882)

    Published 2018
    “…<div><p>Background</p><p>China is the largest developing country with a relatively developed public health system. …”
    Save to List
    Saved in:
  17. 12897
    Thymol and its combination with classical anthelmintics.

    Thymol and its combination with classical anthelmintics. by Guillermina Hernando (553795)

    Published 2019
    Save to List
    Saved in:
  18. 12898
    A Prospective Population Study of Resting Heart Rate and Peak Oxygen Uptake (the HUNT Study, Norway)

    A Prospective Population Study of Resting Heart Rate and Peak Oxygen Uptake (the HUNT Study, Norway) by Javaid Nauman (134772)

    Published 2012
    “…We found a linear association of change in RHR with VO<sub>2peak</sub> (p = 0.03), suggesting that a decrease in RHR over time is likely to be beneficial for cardiovascular fitness. …”
    Save to List
    Saved in:
  19. 12899
    Cumulative and ruptured oocysts.

    Cumulative and ruptured oocysts. by Lauren M. Childs (593877)

    Published 2017
    Save to List
    Saved in:
  20. 12900
    Monocytes and NKG2A cells in risk of SIV<sub>mac251</sub> acquisition.

    Monocytes and NKG2A cells in risk of SIV<sub>mac251</sub> acquisition. by Giacomo Gorini (5693312)

    Published 2020
    “…(A) The percentage of total monocytes and (B) CD14<sup>+</sup>CD16<sup>-</sup> classical monocytes were associated with decreased rate of SIV acquisition. …”
    Save to List
    Saved in:

Search Tools: